JP2018533582A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533582A5
JP2018533582A5 JP2018522126A JP2018522126A JP2018533582A5 JP 2018533582 A5 JP2018533582 A5 JP 2018533582A5 JP 2018522126 A JP2018522126 A JP 2018522126A JP 2018522126 A JP2018522126 A JP 2018522126A JP 2018533582 A5 JP2018533582 A5 JP 2018533582A5
Authority
JP
Japan
Prior art keywords
cancer
use according
pharmaceutically acceptable
acceptable salt
acid ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533582A (ja
JP6833844B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059342 external-priority patent/WO2017075363A1/en
Publication of JP2018533582A publication Critical patent/JP2018533582A/ja
Publication of JP2018533582A5 publication Critical patent/JP2018533582A5/ja
Application granted granted Critical
Publication of JP6833844B2 publication Critical patent/JP6833844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522126A 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法 Active JP6833844B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US62/248,632 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US62/281,964 2016-01-22
US201662323034P 2016-04-15 2016-04-15
US62/323,034 2016-04-15
PCT/US2016/059342 WO2017075363A1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021014795A Division JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2018533582A JP2018533582A (ja) 2018-11-15
JP2018533582A5 true JP2018533582A5 (enExample) 2020-03-19
JP6833844B2 JP6833844B2 (ja) 2021-02-24

Family

ID=58631120

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018522126A Active JP6833844B2 (ja) 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Country Status (36)

Country Link
US (4) US10065974B2 (enExample)
EP (3) EP4011887B1 (enExample)
JP (3) JP6833844B2 (enExample)
KR (2) KR102434308B1 (enExample)
CN (4) CN113150015A (enExample)
AU (3) AU2016343656B2 (enExample)
BR (3) BR122020022275B1 (enExample)
CA (1) CA3003271A1 (enExample)
CL (4) CL2018001134A1 (enExample)
CO (1) CO2018004750A2 (enExample)
CR (3) CR20180282A (enExample)
CY (1) CY1123557T1 (enExample)
DK (2) DK4011887T3 (enExample)
EA (1) EA038276B1 (enExample)
EC (1) ECSP18040250A (enExample)
ES (3) ES2910928T3 (enExample)
HR (1) HRP20201046T1 (enExample)
HU (1) HUE054972T2 (enExample)
IL (3) IL258731B (enExample)
LT (1) LT3368541T (enExample)
MA (2) MA43131B1 (enExample)
MD (1) MD3368541T2 (enExample)
MX (1) MX2018005294A (enExample)
MY (1) MY201783A (enExample)
NZ (1) NZ742742A (enExample)
PH (2) PH12018500899B1 (enExample)
PL (1) PL3368541T3 (enExample)
PT (1) PT3368541T (enExample)
RS (1) RS60695B1 (enExample)
SG (4) SG10201911406TA (enExample)
SI (1) SI3368541T1 (enExample)
SM (1) SMT202000469T1 (enExample)
TW (3) TWI710565B (enExample)
UA (1) UA125289C2 (enExample)
WO (1) WO2017075363A1 (enExample)
ZA (4) ZA201803556B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603364A (en) 2010-04-22 2015-06-26 Mars Inc Inhibitors of arginase and their therapeutic applications
EP2632927B1 (en) 2010-10-26 2016-02-10 Mars, Incorporated Boronates as arginase inhibitors
HUE054972T2 (hu) 2015-10-30 2021-10-28 Calithera Biosciences Inc Készítmények és módszerek az argináz aktivitásának gátlására
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2019005402A (es) 2016-11-08 2019-12-05 Calithera Biosciences Inc Terapias de combinacion del inhibidor de arginasa.
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
EP3621954B1 (en) * 2017-05-12 2022-03-09 Calithera Biosciences, Inc. Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
MX2020008570A (es) 2018-02-17 2020-09-21 Astrazeneca Ab Inhibidores de arginasa y sus metodos de uso.
CR20200445A (es) 2018-03-05 2021-04-27 Arcus Biosciences Inc Inhibidores de la arginasa
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
PL3774843T3 (pl) 2018-03-29 2022-11-14 Molecure Sa Dipeptydowe pochodne piperydyny
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
WO2020102646A2 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
US12240867B2 (en) 2018-12-18 2025-03-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
CN113614095B (zh) * 2019-02-06 2024-08-23 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的烷基硼酸类化合物
PH12021552036A1 (en) * 2019-05-02 2022-05-23 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
CN114127081B (zh) * 2019-07-23 2024-09-13 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
TW202216713A (zh) 2020-07-02 2022-05-01 美商英塞特公司 作為jak2 v617f抑制劑之三環脲化合物
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US20220041630A1 (en) * 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
PE20251706A1 (es) 2022-03-17 2025-07-02 Incyte Corp Compuestos de urea triciclica como inhibidores de v617f de jak2
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
US20240317744A1 (en) 2023-03-13 2024-09-26 Incyte Corporation Bicyclic Ureas As Kinase Inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2296080C (en) 1997-07-29 2005-02-01 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な(−)−ビュープロピオンの薬学的使用
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
AU2001275870A1 (en) 2000-07-06 2002-01-21 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
AU2004263149B2 (en) 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
EP2172655B1 (en) 2007-07-12 2018-10-24 Sanyo Denki Co., Ltd. Dual reversal-rotating type axial blower
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
CA2722992A1 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
DK2389352T3 (da) * 2009-01-26 2019-07-29 Univ Pennsylvania Arginaseinhibitorer og anvendelsesfremgangsmåder
NZ603364A (en) * 2010-04-22 2015-06-26 Mars Inc Inhibitors of arginase and their therapeutic applications
EP2632927B1 (en) * 2010-10-26 2016-02-10 Mars, Incorporated Boronates as arginase inhibitors
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
CA2852936A1 (en) 2011-10-20 2013-04-25 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
IN2014DN09678A (enExample) * 2012-04-18 2015-07-31 Mars Inc
CN111329989A (zh) * 2012-11-02 2020-06-26 药品循环有限责任公司 Tec家族激酶抑制剂辅助疗法
CN105848680A (zh) * 2013-10-25 2016-08-10 药品循环有限责任公司 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
KR20170129896A (ko) * 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
JP2018520352A (ja) 2015-06-23 2018-07-26 カリセラ バイオサイエンシズ,インコーポレイテッド アルギナーゼ活性を阻害するための組成物および方法
HUE054972T2 (hu) 2015-10-30 2021-10-28 Calithera Biosciences Inc Készítmények és módszerek az argináz aktivitásának gátlására
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Similar Documents

Publication Publication Date Title
JP2018533582A5 (enExample)
HRP20201046T1 (hr) Sastavi i metode za inhibitivnu aktivnost arginase
IL292677A (en) Preparations and methods for inhibiting arginase activity
JP2020514271A5 (enExample)
ES2925564T3 (es) Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
ES2821790T3 (es) Moduladores de la vía de estrés integrada
KR102781404B1 (ko) 통합 스트레스 경로의 조정제
JP2018162256A (ja) アポトーシス阻害タンパク質(iap)のアンタゴニスト
EP2408300B1 (en) Amino ester derivatives, salts thereof and methods of use
JP2010533206A5 (enExample)
JP2019519599A (ja) 統合ストレス経路のモジュレーター
TW201945356A (zh) 趨化介素受體調節劑及其用途
EP3802544A1 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
WO2018049271A1 (en) Chemokine receptor modulators and uses thereof
ES2941790T3 (es) Copolímeros dibloque autoensamblados compuestos de PEGMEMA y segmentos poliméricos portadores de fármacos
JP2006507308A5 (enExample)
US20220274964A1 (en) 5-bromo-indirubins
JP2019194194A (ja) 癌を治療するためのhdac8阻害剤
US9399639B2 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
KR20070010125A (ko) 인테그린과 선택적으로 결합하는 피페리디닐 표적화 화합물
JP2019524852A5 (enExample)
JP2025525869A (ja) フェロトーシスを誘導するための組成物および方法
JP2023501038A (ja) 新規の治療的使用
JP2019536783A5 (enExample)
JP2014505052A (ja) 癌の治療および予防用の新規なウレア